The present real-world analysis reports the clinical outcomes and safety profile of CD19-directed CAR-T-cell therapy in 41 patients with R/R DLBCL treated at a regional center in southern Italy between September 2020 and September 2024. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.